Serum procalcitonin in Philadelphia-negative myeloproliferative neoplasms

Summary

Philadelphia-negative myeloproliferative neoplasms (MPNs), essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF), are rare clonal hematopoietic stem cell disorders accompanied by a strong inflammatory milieu, which is directly responsible for constitutional symptoms associated with the disease, such as fever, weight loss or night sweats. Non-hematologists sometimes (and often wrongly) consider the fever in MPN patients to be a symptom of an underlying disease, which may have devastating consequences. Serum procalcitonin (PCT) is a circulating biomarker commonly used to improve the diagnostic accuracy of bacterial infections and to guide antibiotic therapy. The aim of this study was to test whether PCT could aid the clinician in the early diagnosis of bacterial infections in MPNs. This study investigated PCT in 41 ambulatory MPN patients (13 ET, 13 PV and 15 MF) who had no signs of infection and compared it to 10 MPN patients with microbiologically and/or serologically documented bacterial infections. Median PCT in MPN patients was 0.02 ng/mL (range 0.01–0.09 ng/mL). No difference in PCT was found between ET, PV and MF patients (p = 0.993), whereas MPN patients with documented bacterial infections had significantly higher PCT (median PCT 2.45, range 0.90–5.40 ng/mL) when compared to MPN patients with (median PCT 0.03 ng/mL) or without constitutional symptoms (median PCT 0.02 ng/mL; p < 0.001 for both analyses). These results clearly show that PCT should not be considered as a disease biomarker in MPNs and careful clinical assessment for the signs of infection is needed when MPN patients present with fever and high PCT.

This is a preview of subscription content, access via your institution.

Fig. 1

References

  1. 1.

    Geyer HL, Dueck AC, Scherber RM, Mesa RA. Impact of inflammation on myeloproliferative neoplasm symptom development. Mediators Inflamm. 2015;2015:284706.

    Article  Google Scholar 

  2. 2.

    Barbui T, Carobbio A, Finazzi G, et al. Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C‑reactive protein and pentraxin 3. Haematologica. 2011;96(2):315–8.

    CAS  Article  Google Scholar 

  3. 3.

    Lee H. Procalcitonin as a biomarker of infectious diseases. Korean J Intern Med. 2013;28(3):285–91.

    CAS  Article  Google Scholar 

  4. 4.

    Delèvaux I, André M, Colombier M, et al. Can procalcitonin measurement help in differentiating between bacterial infection and other kinds of inflammatory processes? Ann Rheum Dis. 2003;62(4):337–40.

    Article  Google Scholar 

  5. 5.

    Shomali W, Hachem R, Chaftari AM, et al. Can procalcitonin distinguish infectious fever from tumor-related fever in non-neutropenic cancer patients? Cancer. 2012;118(23):5823–9.

    CAS  Article  Google Scholar 

  6. 6.

    Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of m y e l o i d neoplasms and acuteleukemia. Blood. 2016;127:2391–405.

    CAS  Article  Google Scholar 

  7. 7.

    Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779–1790.

    CAS  Article  Google Scholar 

  8. 8.

    Schüttrumpf S, Binder L, Hagemann T, Berkovic D, Trümper L, Binder C. Procalcitonin: a useful discriminator between febrile conditions of different origin in hemato-oncological patients? Ann Hematol. 2003;82(2):98–103.

    Article  Google Scholar 

  9. 9.

    Gac AC, Parienti JJ, Chantepie S, et al. Dynamics of procalcitonin and bacteremia in neutropenic adults with acute myeloid leukemia. Leuk Res. 2011;5(10):1294–6.

    Article  Google Scholar 

  10. 10.

    Kim DY, Lee YS, Ahn S, Chun YH, Lim KS. Procalcitonin as a useful marker of infection in hematooncological patients with fever. Cancer Res Treat. 2011;43(3):176–80.

    Article  Google Scholar 

  11. 11.

    Stölzel F, Babatz J, Thiede C, Siegert G, Illmer T, Ehninger G, et al. Cyclic severe elevated procalcitonin serum levels in patient with post polycythemic myelofibrosis carrying a V617F-JAK2 mutation. Ann Hematol. 2008;87(12):1021–2.

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Ivan Krečak.

Ethics declarations

Conflict of interest

I. Krečak, N. Peran, I. Lapić, V. Gverić-Krečak, F. Krečak, P. Rončević, and N. Duraković declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Krečak, I., Peran, N., Lapić, I. et al. Serum procalcitonin in Philadelphia-negative myeloproliferative neoplasms. Wien Klin Wochenschr 133, 62–64 (2021). https://doi.org/10.1007/s00508-020-01651-8

Download citation

Keywords

  • Biomarker
  • Cytokine
  • Essential thrombocythemia
  • Polycythemia vera
  • Myelofibrosis